Article summary
The CMA has launched a consultation on commitments to address concerns that Vifor Pharma (Vifor) abused its dominant position by making misleading claims about a competitor’s intravenous iron treatment. The CMA has published a Notice of Intention to Accept Commitments offered by Vifor and invited representations from interested third parties on the proposed commitments. The consultation ends on 17 January 2025.
To continue reading this news article, as well as thousands of others like it, sign in with LexisNexis or register for a free trial